FDA Panel Rejects Implanted GLP1-RA-Dosing Device for T2D FDA Panel Rejects Implanted GLP1-RA-Dosing Device for T2D
An implanted device for delivering the GLP-1 receptor agonist exenatide to people with type 2 diabetes received a unanimous no vote from an FDA advisory panel based on safety and other concerns.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - September 22, 2023 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news
Hot weight loss drugs tested as addiction treatments
When the diabetes treatments known as GLP-1 analogs reached the market in 2005, doctors advised patients taking the drugs that they might lose a small amount of weight. Talk about an understatement. Obese people can drop more than 15% of their body weight, studies have found, and two of the medications are now approved by the U.S. Food and Drug Administration (FDA) for weight reduction. A surge in demand for the drugs as slimming treatments has led to shortages. “This class of drugs is exploding in popularity,” says clinical psychologist Joseph Schacht of the University of Colorado School of Medicine.
But patient...
Source: ScienceNOW - August 28, 2023 Category: Science Source Type: news
Hot weight loss drugs tested as addiction treatments
When the diabetes treatments known as GLP-1 analogs reached the market in 2005, doctors advised patients taking the drugs that they might lose a small amount of weight. Talk about an understatement. Obese people can drop more than 15% of their body weight, studies have found, and two of the medications are now approved by the U.S. Food and Drug Administration (FDA) for weight reduction. A surge in demand for the drugs as slimming treatments has led to shortages. “This class of drugs is exploding in popularity,” says clinical psychologist Joseph Schacht of the University of Colorado School of Medicine.
But patient...
Source: ScienceNOW - August 28, 2023 Category: Science Source Type: news
Diabetes Drug Promising for Idiopathic Intracranial Hypertension Diabetes Drug Promising for Idiopathic Intracranial Hypertension
In a small phase 2 trial, subcutaneous exenatide led to a significant reduction in intracranial pressure and number of monthly headaches in patients with IIH.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 16, 2023 Category: Drugs & Pharmacology Tags: Neurology & Neurosurgery News Source Type: news
Effects of Dapagliflozin and Exenatide in T2D Effects of Dapagliflozin and Exenatide in T2D
A new study provides insight into the weight-lowering mechanisms of dapagliflozin and exenatide in obese patients with type 2 diabetes.Journal of Clinical Endocrinology & Metabolism (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 9, 2022 Category: Consumer Health News Tags: Diabetes & Endocrinology Journal Article Source Type: news
Exenatide Linked to Less Hyperglycemia After Stroke Exenatide Linked to Less Hyperglycemia After Stroke
The diabetes drug may offer better control than insulin for hyperglycemia, a common condition following stroke that leads to worse outcomes.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - May 12, 2022 Category: Cardiology Tags: Neurology & Neurosurgery News Source Type: news
FDA OKs Extended-Release Exenatide for Children With T2D FDA OKs Extended-Release Exenatide for Children With T2D
This injectable medication is the second GLP-1 receptor agonist approved for pediatric type 2 diabetes, and the first with once-weekly administration.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 23, 2021 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
Bydureon BCise (exenatide extended-release) Approved in the US for the Treatment of Type 2 Diabetes in Pediatric Patients Ages 10 Years and Older
WILMINGTON, Del.--(BUSINESS WIRE) July 23, 2021--AstraZeneca’s Bydureon BCise (exenatide extended-release), once-weekly injectable suspension has been approved in the US for the treatment of type 2 diabetes (T2D); to improve glycemic control... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - July 23, 2021 Category: Drugs & Pharmacology Source Type: news
Bydureon Bcise (exenatide)
Title: Bydureon Bcise (exenatide)Category: MedicationsCreated: 12/11/2020 12:00:00 AMLast Editorial Review: 12/11/2020 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 11, 2020 Category: Endocrinology Source Type: news
Drug Combo Offers Long-Term Glycemic Control in T2DM
FRIDAY, Nov. 6, 2020 -- For patients with type 2 diabetes and inadequate glycemic control, exenatide once weekly (QW) plus dapagliflozin shows clinically relevant efficacy and is well tolerated over 104 weeks, according to a study published in the... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 6, 2020 Category: Pharmaceuticals Source Type: news
Exenatide in T2DM in Spain: better outcomes, lower cost
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - July 31, 2019 Category: Drugs & Pharmacology Source Type: news
exenatide (Byetta)
Title: exenatide (Byetta)Category: MedicationsCreated: 7/8/2005 12:00:00 AMLast Editorial Review: 3/13/2019 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - March 13, 2019 Category: Endocrinology Source Type: news
Exenatide treatment alleviated symptoms of depression in patients
(IOS Press) Non-motor symptoms of Parkinson's disease (PD), such as depression, apathy, cognitive impairment, sleep disorders, and sensory symptoms, can have a greater impact on health-related quality of life than motor deficits. In a post hoc analysis of the exenatide-PD trial results, investigators found that patients on exenatide treatment experienced improvements in severity of depression, independent of whether their motor function improved. They report their findings in the Journal of Parkinson's Disease. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 1, 2018 Category: International Medicine & Public Health Source Type: news
Incretin/SGLT-2 Combo Efficacy Persists 2 Years
(MedPage Today) -- Exenatide plus dapagliflozin maintained biomarker benefits in long-term study (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - June 26, 2018 Category: Cardiology Source Type: news
AstraZeneca ’ s once-weekly diabetes drug wins expanded FDA approval
AstraZeneca (NYSE:AZN) said today that the FDA approved its extended-release formulation of exenatide, Bydureon, for use as an add-on therapy to basal insulin in adults with Type II diabetes.
The company’s once-weekly GLP-1 injectable was first approved in the U.S. in 2012.
Get the full story at our sister site, Drug Delivery Business News.
The post AstraZeneca’s once-weekly diabetes drug wins expanded FDA approval appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - April 3, 2018 Category: Medical Devices Authors: Sarah Faulkner Tags: Diabetes Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Regulatory/Compliance Wall Street Beat AstraZeneca plc Source Type: news
